375 related articles for article (PubMed ID: 29308922)
1. Uterine smooth muscle tumours with hyperintense area on T
Ando T; Kato H; Furui T; Morishige KI; Goshima S; Matsuo M
Br J Radiol; 2018 Apr; 91(1084):20170767. PubMed ID: 29308922
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
3. Smooth muscle tumours of the uterus: MR imaging malignant predictive features-a 12-year analysis in a referral hospital in Portugal.
Freitas P; Resende-Neves T; Lameira P; Costa M; Dias P; Filipe J; Ferreira J; Félix A; Cunha TM
Arch Gynecol Obstet; 2024 Apr; 309(4):1551-1560. PubMed ID: 38055011
[TBL] [Abstract][Full Text] [Related]
4. Explorative Investigation of Whole-Lesion Histogram MRI Metrics for Differentiating Uterine Leiomyomas and Leiomyosarcomas.
Gerges L; Popiolek D; Rosenkrantz AB
AJR Am J Roentgenol; 2018 May; 210(5):1172-1177. PubMed ID: 29547053
[TBL] [Abstract][Full Text] [Related]
5. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
6. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.
de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP
Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410
[TBL] [Abstract][Full Text] [Related]
7. Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.
Ho KC; Dean Fang YH; Lin G; Ueng SH; Wu TI; Lai CH; Chueh HY; Chao A; Chang TC; Yen TC
Contrast Media Mol Imaging; 2018; 2018():7890241. PubMed ID: 30018513
[TBL] [Abstract][Full Text] [Related]
8. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
9. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma / smooth muscle tumor with uncertain malignant potential and benign leiomyoma.
Lin G; Yang LY; Huang YT; Ng KK; Ng SH; Ueng SH; Chao A; Yen TC; Chang TC; Lai CH
J Magn Reson Imaging; 2016 Feb; 43(2):333-42. PubMed ID: 26383110
[TBL] [Abstract][Full Text] [Related]
11. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
12. Quantitative MR texture analysis for the differentiation of uterine smooth muscle tumors with high signal intensity on T2-weighted imaging.
Kumagai K; Yagi T; Yamazaki M; Tasaki A; Asatani M; Ishikawa H
Medicine (Baltimore); 2023 Aug; 102(31):e34452. PubMed ID: 37543807
[TBL] [Abstract][Full Text] [Related]
13. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
[TBL] [Abstract][Full Text] [Related]
14. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings.
Tanaka YO; Nishida M; Tsunoda H; Okamoto Y; Yoshikawa H
J Magn Reson Imaging; 2004 Dec; 20(6):998-1007. PubMed ID: 15558559
[TBL] [Abstract][Full Text] [Related]
15. Uterine Leiomyosarcoma: Can MRI Differentiate Leiomyosarcoma From Benign Leiomyoma Before Treatment?
DeMulder D; Ascher SM
AJR Am J Roentgenol; 2018 Dec; 211(6):1405-1415. PubMed ID: 30354268
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
17. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
18. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
19. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
20. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
